Vaxess Technologies, Inc

Showcase Sponsor

Vaxess is developing a broadly protective, shelf-stable influenza vaccine as the lead product on the MIMIX platform. The MIMIX patch enables simple sustained-release of biologic drugs in the skin with only five minutes of wear-time. By sustaining antigen presentation in the skin and, by extension, the lymph nodes, for 1-2 weeks, the platform dramatically enhances the strength and breadth of immune responses to vaccines and immunotherapies. Vaxess has partnerships with The Bill and Melinda Gates Foundation, NSF, NIH, and two leading pharmaceutical companies to develop a range of products on the platform.

Sign Up for Event Updates